JP2016513110A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513110A5
JP2016513110A5 JP2015558162A JP2015558162A JP2016513110A5 JP 2016513110 A5 JP2016513110 A5 JP 2016513110A5 JP 2015558162 A JP2015558162 A JP 2015558162A JP 2015558162 A JP2015558162 A JP 2015558162A JP 2016513110 A5 JP2016513110 A5 JP 2016513110A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
modified oligonucleotide
wing
fragment
wing fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015558162A
Other languages
English (en)
Japanese (ja)
Other versions
JP6313789B2 (ja
JP2016513110A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/016546 external-priority patent/WO2014127268A2/en
Publication of JP2016513110A publication Critical patent/JP2016513110A/ja
Publication of JP2016513110A5 publication Critical patent/JP2016513110A5/ja
Application granted granted Critical
Publication of JP6313789B2 publication Critical patent/JP6313789B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015558162A 2013-02-14 2014-02-14 リポタンパク質リパーゼ欠損(lpld)集団におけるアポリポタンパク質c−iii(apociii)発現の調節 Active JP6313789B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361764969P 2013-02-14 2013-02-14
US61/764,969 2013-02-14
US201361880779P 2013-09-20 2013-09-20
US61/880,779 2013-09-20
PCT/US2014/016546 WO2014127268A2 (en) 2013-02-14 2014-02-14 Modulation of apolipoprotein c-iii (apociii) expression in lipoprotein lipase deficient (lpld) populations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018054633A Division JP6681422B2 (ja) 2013-02-14 2018-03-22 リポタンパク質リパーゼ欠損(lpld)集団におけるアポリポタンパク質c−iii(apociii)発現の調節

Publications (3)

Publication Number Publication Date
JP2016513110A JP2016513110A (ja) 2016-05-12
JP2016513110A5 true JP2016513110A5 (cg-RX-API-DMAC7.html) 2017-03-16
JP6313789B2 JP6313789B2 (ja) 2018-04-18

Family

ID=51354689

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015558162A Active JP6313789B2 (ja) 2013-02-14 2014-02-14 リポタンパク質リパーゼ欠損(lpld)集団におけるアポリポタンパク質c−iii(apociii)発現の調節
JP2018054633A Active JP6681422B2 (ja) 2013-02-14 2018-03-22 リポタンパク質リパーゼ欠損(lpld)集団におけるアポリポタンパク質c−iii(apociii)発現の調節
JP2020050456A Withdrawn JP2020111594A (ja) 2013-02-14 2020-03-23 リポタンパク質リパーゼ欠損(lpld)集団におけるアポリポタンパク質c−iii(apociii)発現の調節

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018054633A Active JP6681422B2 (ja) 2013-02-14 2018-03-22 リポタンパク質リパーゼ欠損(lpld)集団におけるアポリポタンパク質c−iii(apociii)発現の調節
JP2020050456A Withdrawn JP2020111594A (ja) 2013-02-14 2020-03-23 リポタンパク質リパーゼ欠損(lpld)集団におけるアポリポタンパク質c−iii(apociii)発現の調節

Country Status (16)

Country Link
US (4) US9593333B2 (cg-RX-API-DMAC7.html)
EP (2) EP2956176B1 (cg-RX-API-DMAC7.html)
JP (3) JP6313789B2 (cg-RX-API-DMAC7.html)
KR (2) KR20200123263A (cg-RX-API-DMAC7.html)
CN (2) CN108743943A (cg-RX-API-DMAC7.html)
AU (3) AU2014216137B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015019515A8 (cg-RX-API-DMAC7.html)
CA (2) CA3170716A1 (cg-RX-API-DMAC7.html)
DK (1) DK2956176T3 (cg-RX-API-DMAC7.html)
ES (2) ES2680599T3 (cg-RX-API-DMAC7.html)
IL (2) IL240338B (cg-RX-API-DMAC7.html)
MX (2) MX368155B (cg-RX-API-DMAC7.html)
NZ (1) NZ631119A (cg-RX-API-DMAC7.html)
RU (2) RU2018121529A (cg-RX-API-DMAC7.html)
WO (1) WO2014127268A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201505628B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107854478A (zh) * 2011-04-27 2018-03-30 Ionis制药公司 载脂蛋白ciii(apociii)表达的调节
RU2018121529A (ru) * 2013-02-14 2019-03-06 Ионис Фармасьютикалз, Инк. МОДУЛИРОВАНИЕ ЭКСПРЕССИИ АПОЛИПОПРОТЕИНА C-III (AроCIII) У ЛЮДЕЙ С ДЕФИЦИТОМ ЛИПОПРОТЕИНЛИПАЗЫ (LPLD)
JP6694382B2 (ja) * 2013-06-21 2020-05-13 アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. 標的核酸を調節するための組成物および方法
EP3270931A4 (en) * 2015-02-27 2018-10-03 Ionis Pharmaceuticals, Inc. Modulation of apolipoprotein c-iii (apociii) expression in lipodystrophy populations
JP2019525772A (ja) 2016-07-08 2019-09-12 スターテン・バイオテクノロジー・ベー・フェー 抗apoc3抗体およびその使用方法
JP2019535839A (ja) 2016-11-29 2019-12-12 ピュアテック ヘルス エルエルシー 治療剤の送達のためのエクソソーム
MA50958A (fr) 2017-04-21 2020-10-14 Staten Biotechnology B V Anticorps anti-apoc3 et leurs méthodes d'utilisation
CN120884604A (zh) 2017-06-02 2025-11-04 波涛生命科学有限公司 寡核苷酸组合物及其使用方法
KR20200074975A (ko) 2017-10-31 2020-06-25 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
TWI844541B (zh) 2018-05-11 2024-06-11 新加坡商波濤生命科學有限公司 寡核苷酸組成物及其使用方法
WO2022072244A1 (en) * 2020-10-02 2022-04-07 Ionis Pharmaceuticals, Inc. Methods for reducing apociii expression
CN116814621B (zh) * 2022-08-05 2025-09-09 厦门甘宝利生物医药有限公司 一种抑制apoc3基因表达的rna抑制剂及其应用
WO2025110984A1 (en) * 2023-11-21 2025-05-30 Hydrogene Therapeutics, Inc. Compositions and methods for treating wilson's disease

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2699808A (en) 1944-10-06 1955-01-18 Mark W Lowe Apparatus for peeling tomatoes
US2699508A (en) 1951-12-21 1955-01-11 Selectronics Inc Method of mounting and construction of mounting for low frequency piezoelectric crystals
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
JPH05504552A (ja) 1989-10-24 1993-07-15 ギリアド サイエンシズ,インコーポレイテッド 2’位が改変されたオリゴヌクレオチド
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
DK0455905T3 (da) 1990-05-11 1998-12-07 Microprobe Corp Dipsticks til nukleinsyrehybridiseringsassays og fremgangsmåde til kovalent immobilisering af oligonukleotider
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
ES2103918T3 (es) 1991-10-17 1997-10-01 Ciba Geigy Ag Nucleosidos biciclicos, oligonucleotidos, procedimiento para su obtencion y productos intermedios.
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
JPH08504559A (ja) 1992-12-14 1996-05-14 ハネウエル・インコーポレーテッド 個別に制御される冗長巻線を有するモータシステム
DK0691968T3 (da) 1993-03-30 1998-02-23 Sanofi Sa Acykliske nukleosid-analoge og oligonukleotidsekvenser indeholdende disse
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5656408A (en) 1996-04-29 1997-08-12 Xerox Corporation Coated carrier particles
US7875733B2 (en) 2003-09-18 2011-01-25 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
JP4236812B2 (ja) 1997-09-12 2009-03-11 エクシコン エ/エス オリゴヌクレオチド類似体
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
US6043352A (en) 1998-08-07 2000-03-28 Isis Pharmaceuticals, Inc. 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
BR0009884A (pt) 1999-04-21 2002-01-08 American Home Prod Processos e composições para a inibição da função das sequências de polinucleotìdeos
CN102180924A (zh) 1999-05-04 2011-09-14 桑塔里斯制药公司 L-核糖-lna类似物
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
ATE322493T1 (de) 1999-12-30 2006-04-15 Leuven K U Res & Dev Cyclohexennukleinsäuren
WO2003004602A2 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
JP2006500012A (ja) 2002-07-31 2006-01-05 ヌクレオニクス インコーポレーティッド 二本鎖rnaの構造および構築物、並びにその作製法および使用法
AU2003284323A1 (en) 2002-10-18 2004-05-04 Alnylam Pharmaceuticals Inc Double-stranded rna structures and constructs, and methods for generating and using the same
US8604183B2 (en) 2002-11-05 2013-12-10 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
EP1562971B1 (en) 2002-11-05 2014-02-12 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
EP2314691A3 (en) 2002-11-14 2012-01-18 Dharmacon, Inc. Fuctional and hyperfunctional siRNA
US6673661B1 (en) 2002-12-20 2004-01-06 Taiwan Semiconductor Manufacturing Co., Ltd. Self-aligned method for forming dual gate thin film transistor (TFT) device
US7598227B2 (en) * 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
US7427672B2 (en) 2003-08-28 2008-09-23 Takeshi Imanishi Artificial nucleic acids of n-o bond crosslinkage type
EP1766071A4 (en) 2004-06-03 2009-11-11 Isis Pharmaceuticals Inc DOUBLE-STRONG COMPOSITIONS WITH DIFFERENTLY MODIFIED STRANDS FOR USE IN GENE MODULATION
US20080261905A1 (en) 2004-11-08 2008-10-23 K.U. Leuven Research And Development Modified Nucleosides for Rna Interference
CN102908630B (zh) 2006-01-27 2014-11-19 Isis制药公司 6-修饰的双环核酸类似物
EP2066684B1 (en) 2006-05-11 2012-07-18 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
EP2125852B1 (en) 2007-02-15 2016-04-06 Ionis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
ES2388590T3 (es) 2007-05-30 2012-10-16 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos con puente aminometileno N-sustituido.
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
WO2009006478A2 (en) 2007-07-05 2009-01-08 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
US8530640B2 (en) 2008-02-07 2013-09-10 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
US8501805B2 (en) 2008-09-24 2013-08-06 Isis Pharmaceuticals, Inc. Substituted alpha-L-bicyclic nucleosides
US8604192B2 (en) 2008-09-24 2013-12-10 Isis Pharmaceuticals, Inc. Cyclohexenyl nucleic acids analogs
WO2010080953A1 (en) 2009-01-08 2010-07-15 Isis Pharmaceuticals, Inc. Transgenic murine model of human lipoprotein metabolism, hypercholesterolemia and cardiovascular disease
AT507215B1 (de) 2009-01-14 2010-03-15 Boehler Edelstahl Gmbh & Co Kg Verschleissbeständiger werkstoff
US9023820B2 (en) 2009-01-26 2015-05-05 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein C-III expression
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
EP2480667A4 (en) * 2009-09-25 2013-07-03 Isis Pharmaceuticals Inc MODULATION OF TTC39 EXPRESSION FOR HDL INCREASE
JP2013523746A (ja) * 2010-03-30 2013-06-17 ノバルティス アーゲー Dgat1阻害剤の使用
WO2011139702A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. Modified nucleosides and oligomeric compounds prepared therefrom
CN107854478A (zh) 2011-04-27 2018-03-30 Ionis制药公司 载脂蛋白ciii(apociii)表达的调节
EP3693464A3 (en) 2011-06-21 2020-12-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
NZ631071A (en) * 2012-05-24 2017-02-24 Ionis Pharmaceuticals Inc Methods and compositions for modulating apolipoprotein(a) expression
US9984408B1 (en) 2012-05-30 2018-05-29 Amazon Technologies, Inc. Method, medium, and system for live video cooperative shopping
RU2018121529A (ru) * 2013-02-14 2019-03-06 Ионис Фармасьютикалз, Инк. МОДУЛИРОВАНИЕ ЭКСПРЕССИИ АПОЛИПОПРОТЕИНА C-III (AроCIII) У ЛЮДЕЙ С ДЕФИЦИТОМ ЛИПОПРОТЕИНЛИПАЗЫ (LPLD)
KR102138781B1 (ko) * 2013-05-01 2020-07-28 아이오니스 파마수티컬즈, 인코포레이티드 아포지질단백질 c-iii 발현을 조절하는 조성물 및 방법
US9778708B1 (en) 2016-07-18 2017-10-03 Lenovo Enterprise Solutions (Singapore) Pte. Ltd. Dual sided latching retainer for computer modules

Similar Documents

Publication Publication Date Title
JP2016513110A5 (cg-RX-API-DMAC7.html)
JP2020111594A5 (cg-RX-API-DMAC7.html)
JP2014516516A5 (cg-RX-API-DMAC7.html)
RU2501803C2 (ru) Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4)
RU2017120536A (ru) Способы и композиции для модулирования экспрессии аполипопротеина (а)
JP6203707B2 (ja) アポリポタンパク質ciii(apociii)発現の調節
JP6313789B2 (ja) リポタンパク質リパーゼ欠損(lpld)集団におけるアポリポタンパク質c−iii(apociii)発現の調節
RU2015151200A (ru) Композиции и способы модулирования экспрессии аполипопротеина (а)
JP2012050438A5 (cg-RX-API-DMAC7.html)
JP2016533717A5 (cg-RX-API-DMAC7.html)
JP2010500290A5 (cg-RX-API-DMAC7.html)
RU2012114198A (ru) Модуляция экспрессии гентингтина
JP2010510807A5 (cg-RX-API-DMAC7.html)
JP2016530882A5 (cg-RX-API-DMAC7.html)
JP2019088329A5 (cg-RX-API-DMAC7.html)
JP2013526860A5 (cg-RX-API-DMAC7.html)
JP2014513954A5 (cg-RX-API-DMAC7.html)
JP2017505116A5 (cg-RX-API-DMAC7.html)
RU2011119479A (ru) Модуляция экспрессии фактора 11
JP2016522817A5 (cg-RX-API-DMAC7.html)
RU2014115215A (ru) Антисмысловая регуляция экспрессии gcgr
JP2006141402A5 (cg-RX-API-DMAC7.html)
Shukla et al. Novel non-biologic targets for inflammatory bowel disease
CN117899079A (zh) 癌症的治疗方法
JP2011515357A5 (cg-RX-API-DMAC7.html)